Collaboration to Advance Addiction Treatment Research
CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION
In a groundbreaking initiative, Tessara Therapeutics, Psylo, and the University of Sydney have successfully obtained a substantial grant of $3 million under the Cooperative Research Centres Projects (CRC-P). This significant funding, complemented by matching contributions from the collaborators, brings the total investment to an impressive $6.2 million. This collaboration marks a pivotal step forward in the development of neuroplastogens aimed at treating substance use disorders, particularly focusing on the pressing issue of methamphetamine addiction.
The Urgency of Addressing Methamphetamine Addiction
Methamphetamine addiction has emerged as a severe public health concern, with current treatment options being limited and often ineffective. This situation underscores the critical need for new and innovative therapeutic strategies. By harnessing Tessara's advanced RealBrain® microtissue technology and Psylo's unique neuroplastogens, combined with the neuroscience expertise at the University of Sydney, this partnership aims to tackle this urgent challenge head-on.
Understanding Neuroplastogens
Neuroplastogens represent a novel category of compounds that have the potential to promote neuroplasticity—the brain's remarkable ability to adapt and form new neural connections. Unlike conventional treatments that primarily target symptoms, neuroplastogens aspire to restore brain functionality directly by encouraging the growth and reorganization of neural pathways. This fresh approach signifies the potential for faster and more efficient interventions for addiction and various mental health issues.
Expert Insights on Collaboration
Dr. Christos Papadimitriou, the CEO and Managing Director of Tessara Therapeutics, expressed enthusiasm about the collaboration, stating, "This grant offers an exhilarating opportunity to integrate the expertise of Tessara, Psylo, and the University of Sydney in developing solutions that address urgent medical needs. Our high-throughput human cell-based microtissues accurately model brain function, significantly enhancing the drug discovery process for treating addiction."
Psylo’s Mission in Mental Health Care
Joshua Ismin, CEO and co-founder of Psylo, highlighted their company's commitment to mental health by saying, "At Psylo, we aim to fill crucial gaps in mental health care through next-generation neuroplastogens. This collaboration not only accelerates our drug development efforts but also brings us closer to delivering meaningful solutions for addiction-related challenges."
Long-term Goals and Innovations in Research
The primary objectives of this project are to significantly reduce both the time and financial resources required for neuroplastogen discovery. This initiative promises to create quicker and more precise avenues for treating substance use disorders.
Dr. Nick Everett, a Research Fellow specializing in behavioral neuroscience at the University of Sydney’s Brain and Mind Centre, mentioned, "This collaboration signifies a major advancement in creating research models that truly reflect human biology, facilitating more accurate testing of novel therapies. We believe this initiative could revolutionize the approach to developing addiction therapeutics."
Funding and Support for Research Initiatives
Formally scheduled to run from January 2025 to December 2027, this initiative is expected to not only yield promising neuroplastogen candidates but also enhance research capabilities in neuroplasticity. It aims to improve access to high-efficiency preclinical models while promoting sustainable research practices within the realm of drug discovery. The funding for this vital project has been provided by the Australian Government under the Cooperative Research Centres Projects Round 16.
Company Insights
About Tessara Therapeutics
Tessara Therapeutics is a pioneering biotechnology company dedicated to developing innovative drug discovery technologies and therapeutic interventions aimed at addressing mental health disorders. Their forward-thinking methodology seeks to transform preclinical drug development, enhancing patient outcomes, and reducing the time needed for the introduction of new treatments.
About Psylo
Psylo is committed to the advancement of next-generation neuroplastogens intended for the treatment of disorders affecting the central nervous system. Leveraging AI-driven drug design alongside translational biomarkers, Psylo aspires to make a significant impact on the neurotherapeutic landscape, enhancing the well-being of millions globally.
About the University of Sydney
As Australia’s first university, the University of Sydney ranks among the top 20 global institutions for higher education and research. Known for its outstanding programs in neuroscience, psychology, and mental health, the university collaborates closely with industry partners to revolutionize the understanding and treatment of mental health conditions.
Frequently Asked Questions
What is the main focus of the grant received by Tessara Therapeutics and its partners?
The grant primarily focuses on developing neuroplastogens for the treatment of substance use disorders, particularly methamphetamine addiction.
Who are the collaborators in this project?
The key collaborators in this initiative are Tessara Therapeutics, Psylo, and the University of Sydney.
What innovative technology is being utilized in this research?
The research employs Tessara's RealBrain® microtissue technology and Psylo's neuroplastogens to promote neuroplasticity in treating addictions.
What are neuroplastogens?
Neuroplastogens are a new class of compounds designed to enhance neuroplasticity, helping the brain to adapt and form new neural connections, targeting the restoration of brain function directly.
How long is the project expected to run?
The project is scheduled to commence in January 2025 and conclude in December 2027.
